



CASE D0066 NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV305490009US
Express Mail Label Number

April 20, 2004
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FEDER ET AL.

APPLICATION NO: 10/029,347

FILED: DECEMBER 20, 2001

FOR: NOVEL HUMAN LEUCINE-RICH REPEAT CONTAINING PROTEIN
EXPRESSED PREDOMINATELY IN SMALL INTESTINE, HLRRS1

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT


Sir:

Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289
Date: April 20, 2004


Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV305490009US
Express Mail Label Number

April 20, 2004
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FEDER ET AL.

APPLICATION NO: 10/029,347

FILED: DECEMBER 20, 2001

FOR: NOVEL HUMAN LEUCINE-RICH REPEAT CONTAINING PROTEIN
EXPRESSED PREDOMINATELY IN SMALL INTESTINE, HLRRS11

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the
references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.


04/22/2004 MBLANCO 00000008 193880 10029347

02 FC:1806 180.00 DA

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289




Stephen C. D'Amico
Agent for Applicants
Reg. No. 46,652

Date: April 20, 2004

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)


ATTY. DOCKET NO.
 D0066 NP
APPLICATION NO.
 10/029,347
APPLICANT
 FEDER ET AL.
FILING DATE
 DECEMBER 20, 2001

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Baldwin, Albert S., Jr., "THE NF-kB AND IκB PROTEINS: New Discoveries and Insights", Annu. Rev. Immunol., Vol. 14, pp. 649-81 (1996)
	AS	Rahman, Irfan, "Regulation of Nuclear Factor-kB, Activator Protein-1, and Glutathione Levels by Tumor Necrosis Factor-α and Dexamethasone in Alveolar Epithelial Cells", Biochem. Pharmacology, Vol. 60, pp 1041-1049 (2000)
	AT	Brown, et al., "Mutual regulation of the transcriptional activator NF-kB and its inhibitor, IκB-α", Proc. Natl. Acad. Sci., Vol. 90, pp. 2532-2536 (1993)


EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
D0066 NP
APPLICATION NO.
10/029,347
APPLICANT
FEDER ET AL.
FILING DATE
DECEMBER 20, 2001

Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Baeuerle, et al., "I κ B: A Specific Inhibitor of the NF- κ B Transcription Factor", Science, Vol. 242, pp. 540-546 (242)
2AB	Baeuerle, et al., "Activation of DNA-Binding Activity in an Apparently Cytoplasmic Precursor of the NF- κ B Transcription Factor", Cell, Vol. 53, pp. 211-217 (1988)
2AC	Ganchi, et al., "I κ B/MAD-3 Masks the Nuclear Localization Signal of NF- κ B p65 and Requires the Transactivation Domain to Inhibit NF- κ B p65 DNA Binding", Molec. Biol. Cell, Vol. 3, pp. 1339-1352 (1992)
2AD	Beg, et al., "The I κ B proteins: multifunctional regulators of Rel/NF- κ B transcription factors", Genes & Develop., Vol. 7, pp. 2064-2070 (1993)
2AE	Liou, et al., "Regulation of the NF- κ B/rel transcription factor and I κ B inhibitor system", Current Opinion in Cell Biol., Vol. 5, pp. 477-487 (1993)
AF	
AG	
AH	
AI	
AJ	
AK	
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.